ReviewAnnals of translational medicine2019
Liquid biopsy for lung cancers: an update on recent developments.
Review in Annals of translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- Role of circulating tumor cells in diagnosis of lung cancer: a systematic review and meta-analysis.The Journal of international medical research · 2021Pooled it
- MicroRNA-299-3p as a potential marker of tumor size in non-small cell lung cancer.Turk gogus kalp damar cerrahisi dergisi · 2026Article
- Liquid biopsy - a narrative review with an update on current US governmental clinical trials targeting immunotherapy.Future science OA · 2025Review
- Emerging biomarkers for early cancer detection and diagnosis: challenges, innovations, and clinical perspectives.European journal of medical research · 2025Review
- Precision Medicine in Lung Cancer Screening: A Paradigm Shift in Early Detection-Precision Screening for Lung Cancer.Diagnostics (Basel, Switzerland) · 2025Review
- Identification and validation of a DNA methylation-block prognostic model in non-small cell lung cancer patients.BMC cancer · 2025Article
- Liquid biopsy in cancer current: status, challenges and future prospects.Signal transduction and targeted therapy · 2024Review
- Review
- Innovation in Non-Invasive Diagnosis and Disease Monitoring for Meningiomas.International journal of molecular sciences · 2024Review
- Plasticity of circulating tumor cells in small cell lung cancer.Scientific reports · 2023Article
- The Impact of Liquid Biopsies Positive forDiagnostics (Basel, Switzerland) · 2023Article
- Liquid Biopsy for Lung Cancer: Up-to-Date and Perspectives for Screening Programs.International journal of molecular sciences · 2023Review
- Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer.Frontiers in immunology · 2023Review
- Detection of circulating rare cells benefitted the diagnosis of malignant solitary pulmonary nodules.Journal of cancer research and clinical oncology · 2022Article
- Real-World Patient Characteristics, Treatment Patterns, and Mutation Testing Patterns Among US Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations.Advances in therapy · 2022Observational
- Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments.Molecular cancer · 2022Review
- Optical biosensing of markers of mucosal inflammation.Nanomedicine : nanotechnology, biology, and medicine · 2022Article
- Article
- Plasma Cell-Free DNA Genotyping: From an Emerging Concept to a Standard-of-Care Tool in Metastatic Non-Small Cell Lung Cancer.The oncologist · 2021Review
- Diagnostic and prognostic biomarkers in oligometastatic non-small cell lung cancer: a literature review.Translational lung cancer research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liquid biopsy in lung cancer is evolving as an important added tool for screening, early detection, monitoring, and even prognostication of lung cancer. Guidelines and expert recommendations for its use in practice are available and there are specific scenarios in which liquid biopsy is actively being adopted. Several biomarkers, from which important tumor genomic information is obtained, are currently the subject of ongoing investigation. In this review, we summarize the available data on each specific biomarker and provide an overview on how they play a role in current clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.